Germantown-based Cambridge Major Laboratories Inc. (CML), a global leader in pharmaceutical API development and manufacturing, and AAIPharma Services Corp. today announced the appointment of Patrick Walsh as the chief executive officer of the merged company.
Kyle Bradford, American Capital managing director, said, “We are very excited to be working with Pat on the continued growth of CML and AAIPharma. He is a well-respected CEO with over 30 years of leadership experience in the pharmaceutical industry. AAIPharma’s industry-leading formulation development and analytical service offerings complement CML’s world-class API development and manufacturing capabilities, and the combination creates an industry-leading contract development and manufacturing organization (“CDMO”) that is positioned for significant growth and expansion.”
“The client response to our merger announcement has been very positive,” Walsh said. “Providing an integrated service offering, coupled with a stellar regulatory track record, allows the combined business to exceed the expectations of our global pharma client base.”
